Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Feb;111(2):230-232.
doi: 10.1007/s00392-021-01946-4. Epub 2021 Nov 3.

A case of myocarditis in a 60-year-old man 48 h after mRNA vaccination against SARS-CoV2

Dirk Habedank  1   2 , Antonia Lagast  3 , Monica Novoa-Usme  3 , Iskandar Atmowihardjo  3
Affiliations
Case Reports

A case of myocarditis in a 60-year-old man 48 h after mRNA vaccination against SARS-CoV2

Dirk Habedank et al. Clin Res Cardiol. 2022 Feb.
No abstract available

Keywords: 60 years old; MRI; Myocarditis; SARS-CoV2; Troponin; Vaccination; mRNA; mRNA-1273.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Fig. 1
Fig. 1
a Cardiac MRI, T2 sequence, arrow indicating focal edema anterolateral medial (criterion 1 in ESC definition). b Short-axis view showing subepicardial gadolinium late enhancement anterolateral medial (criterion 3 in ESC definition [4]). c Corresponding four-chamber view
See this image and copyright information in PMC

References

    1. Gargano JW, Wallace M, Hadler SC, Langley G, Su JR, Oster ME, Broder KR, Gee J, Weintraub E, Shimabukuro T, Scobie HM, Moulia D, Markowitz LE, Wharton M, McNally VV, Romero JR, Keipp Talbot H, Lee GM, Daley MF, Oliver SE. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices—united states. MMWR Morb Mortal Wkly Rep. 2021;70(27):977–982. - PMC - PubMed
    1. Sicherheitsbericht. Verdachtsfälle von Nebenwirkungen und Impfkomplikationen nach Impfung zum Schutz vor COVID-19 seit Beginn der Impfkampagne am 27.12.2020 bis zum 31.7.2021. Tabelle 5 Seite 17. http://pei.de/dossiers/sicherheitsberichte
    1. Rosenblum HG, Hadler SC, Moulia D, Shimabukuro TT, Su JR, Tepper NK, Ess KC, Jane Woo E, Mba-Jonas A, Alimchandani M, Nair N, Klein NP, Hanson KE, Markowitz LE, Wharton M, McNally VV, Romero JR, Keipp Talbot H, Lee GM, Daley MF, Mbaeyi SA, Oliver SE. Use of COVID-19 vaccines after reports of adverse events among adult recipients of janssen (johnson & johnson) and mRNA COVID-19 vaccines (pfizer-BioNTech and moderna): update from the advisory committee on immunization practices—united states. MMWR Morb Mortal Wkly Rep. 2021;70(32):1094–1099. - PMC - PubMed
    1. Caforio ALP, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB, Fu M, Helio T, Heymans S, Jahns R, Klingel K, Linhart A, Maisch B, McKenna W, Mogensen J, Pinto YM, Ristic A, Schultheiss H-P, Seggewiss H, Tavazzi L, Thiene G, Yilmaz A, Charron P, Elliott PM. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the european society of cardiology working group on myocardial and pericardial diseases. Eur Heart J. 2013;34(33):2636–2648. - PubMed
    1. Khogali F, Abdelrahman R. Unusual presentation of acute perimyocarditis following SARS-COV-2 mRNA-1237 moderna vaccination. Cureus. 2021;13(7):e16590. - PMC - PubMed

Substances